NCT00443209View on ClinicalTrials.gov

Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,068

Participants

Timeline

Start Date

February 21, 2007

Primary Completion Date

January 22, 2009

Study Completion Date

January 22, 2009

Conditions
Migraine
Interventions
DRUG

Telcagepant 300 mg soft gel capsules

One capsule taken orally at onset of migraine

DRUG

Telcagepant 280 mg tablets

One tablet taken orally at onset of migraine

DRUG

Rizatriptan 10 mg tablets

One tablet taken orally at onset of migraine

DRUG

Placebo to telcagepant capsules

One capsule taken orally at onset of migraine

DRUG

Placebo to telcagepant tablets

One tablet taken orally at onset of migraine

DRUG

Placebo to rizatriptan tablets

One tablet taken orally at onset of migraine

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00443209 - Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) | Biotech Hunter | Biotech Hunter